Clinical candidate and genistein analogue AXP107‐11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein‐coupled estrogen receptor signaling

Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade

(2018) Christopher A Natale et al.   eLife

Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma

(2018) Ioannis Pozios et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma

(2018) Hendrik Seeliger et al.   BMC CANCER

GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment

(2018) Ernesto Cortes et al.   EMBO REPORTS

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

(2018) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

A pathology atlas of the human cancer transcriptome

(2017) Mathias Uhlen et al.   SCIENCE

Insufficient antibody validation challenges oestrogen receptor beta research

(2017) Sandra Andersson et al.   Nature Communications

Molecular mechanisms involved in the non-monotonic effect of bisphenol-a on Ca2+ entry in mouse pancreatic β-cells

(2017) Sabrina Villar-Pazos et al.   Scientific Reports

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma

(2016) D. Roife et al.   CLINICAL CANCER RESEARCH

Understanding genistein in cancer: The “good” and the “bad” effects: A review

(2016) Maria Russo et al.   FOOD CHEMISTRY

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

(2016) Andrea Wang-Gillam et al.   LANCET

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer

(2016) Johannes-Matthias Löhr et al.   PANCREATOLOGY

Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives

(2015) Alina Uifălean et al.   MOLECULES

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Genistein and Cancer: Current Status, Challenges, and Future Directions

(2015) Carmela Spagnuolo et al.   Advances in Nutrition

Phytochemicals Perturb Membranes and Promiscuously Alter Protein Function

(2014) Helgi I. Ingólfsson et al.   ACS Chemical Biology

Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

(2014) Lucas de Sousa Cavalcante et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The Orphan Nuclear Receptor NR4A1 (Nur77) Regulates Oxidative and Endoplasmic Reticulum Stress in Pancreatic Cancer Cells

(2014) Syng-Ook Lee et al.   MOLECULAR CANCER RESEARCH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coexposure to Phytoestrogens and Bisphenol A Mimics Estrogenic Effects in an Additive Manner

(2013) Anne Katchy et al.   TOXICOLOGICAL SCIENCES

MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes

(2013) S Nath et al.   Oncogenesis

G protein-coupled estrogen receptor

(2012) Eric R. Prossnitz   CRITICAL CARE MEDICINE

The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family

(2012) N Skrypek et al.   ONCOGENE

G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling

(2011) Bengt-Olof Nilsson et al.   BRITISH JOURNAL OF PHARMACOLOGY

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

The G-protein-coupled estrogen receptor GPER in health and disease

(2011) Eric R. Prossnitz et al.   Nature Reviews Endocrinology

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy

(2010) S Singh et al.   BRITISH JOURNAL OF CANCER

Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor  1- and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer

(2009) C. Geismann et al.   CANCER RESEARCH

Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis

(2009) Eric Blasko et al.   JOURNAL OF NEUROIMMUNOLOGY

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

(2009) Michael P Kim et al.   Nature Protocols

Multi-targeted therapy of cancer by genistein

(2008) Sanjeev Banerjee et al.   CANCER LETTERS

Cytotoxicity of the isoflavone genistein in NIH 3T3 cells

(2008) A RUCINSKA et al.   CELL BIOLOGY INTERNATIONAL

Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis

(2008) P Pinton et al.   ONCOGENE